Cyfuse Biomedical K.K. (TYO:4892)
Japan flag Japan · Delayed Price · Currency is JPY
492.00
-11.00 (-2.19%)
Nov 18, 2026, 10:49 AM JST

Cyfuse Biomedical K.K. Income Statement

Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2832305461374708
Revenue Growth
217.98%325.93%-11.47%-83.69%-47.17%416.79%
Cost of Revenue
1241173823133137
Gross Profit
1591131638241571
Selling, General & Admin
495512428351346500
Research & Development
416416469375303-
Operating Expenses
925942912735666500
Operating Income
-766-829-896-697-42571
Interest Expense
-23-15-10-10-7-5
Interest & Investment Income
63----
Currency Exchange Gain (Loss)
-----1-
Other Non Operating Income (Expenses)
98036121-78
EBT Excluding Unusual Items
-774-761-870-586-433144
Other Unusual Items
-----38-
Pretax Income
-774-761-870-586-471144
Income Tax Expense
222322
Net Income to Company
--763-872-589-473142
Net Income
-776-763-872-589-473142
Net Income to Common
-776-763-872-589-473142
Net Income Growth
------
Shares Outstanding (Basic)
1098831
Shares Outstanding (Diluted)
1098831
Shares Change
17.72%9.33%3.05%192.85%432.99%-
EPS (Basic)
-78.17-86.69-108.31-75.39-177.31283.72
EPS (Diluted)
-78.17-86.69-108.31-75.39-177.31283.72
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
--581-768-581-631-
Free Cash Flow Per Share
--66.01-95.40-74.37-236.54-
Gross Margin
56.18%49.13%29.63%62.30%64.44%80.65%
Operating Margin
-270.67%-360.44%-1659.26%-1142.62%-113.64%10.03%
Profit Margin
-274.20%-331.74%-1614.82%-965.57%-126.47%20.06%
Free Cash Flow Margin
--252.61%-1422.22%-952.46%-168.72%-
EBITDA
-729.75-792-858-657-362-
EBITDA Margin
-257.86%----96.79%-
D&A For EBITDA
36.2537384063-
EBIT
-766-829-896-697-42571
EBIT Margin
-270.67%----113.64%10.03%
Effective Tax Rate
-----1.39%